POZEN (POZN) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
POZEN Reports First Quarter 2015 Results
May 8, 2015 7:30 AM EDTCHAPEL HILL, N.C.--(BUSINESS WIRE)-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015.
Corporate Highlights
Q1 2015 was the fourth consecutive quarter of positive cash flow. Royalty revenue for Q1 2015 was $4.4 million compared to $4.5 million for Q1 2014. Q1 2015 expenses decreased by $0.4 million to $4.2 million compared to Q1 2014. In Q1 2015, POZEN announced the issuance of a patent by... More